Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 143, Issue 4, pp 459–462 | Cite as

Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer

  • E. S. Gershtein
  • E. A. Korotkova
  • A. M. Shcherbakov
  • V. V. Prorokov
  • D. A. Golovkov
  • N. E. Kushlinskii
Article

Abstract

Enzyme immunoassays showed significantly elevated content of matrix metalloproteinase 7 and type 1 tissue inhibitor of metalloproteinases in tumors compared to adjacent histologically unchanged mucosa of patients with colorectal cancer; the levels of metalloproteinase 9 and type 4 tissue inhibitor of metalloproteinases were virtually the same in the tumors and mucosa. Plasma concentrations of the studied proteins did not correlate with their levels in the tumor, did not surpass the normal, and did not decease after removal of the primary tumor in the majority of patients.

Key Words

matrix metalloproteinase 7 matrix metalloproteinase 9 type 1 tissue inhibitor of matrix metalloproteinases type 4 tissue inhibitor of matrix metalloproteinases colorectal cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    N. E. Kushlinskii and E. S. Gershtein, Byull. Eksp. Biol. Med., 131, No. 7, 81–87 (2001).Google Scholar
  2. 2.
    N. I. Solovyova, Zh. Bioorg. Khim., 24, 217–226 (1998).Google Scholar
  3. 3.
    Y. Adachi, F. Itoh, H. Yamamoto, et al., Tumour Biol., 22, No. 4, 247–253 (2001).PubMedCrossRefGoogle Scholar
  4. 4.
    J. H. Hammer, L. Basse, M. N. Svendsen, et al., Colorectal Dis., 8, No. 3, 168–172 (2006).PubMedCrossRefGoogle Scholar
  5. 5.
    F. Lizarraga, M. Espinosa, V. Maldonado, and J. Melendez-Zajgla, Anticancer Res., 25, 623–627 (2005).PubMedGoogle Scholar
  6. 6.
    W. J. Lubbe, Z. Y. Zhou, W. Fu, et al., Clin. Cancer Res., 12, No. 6, 1876–1882 (2006).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Malhotra, E. Newman, D. Eisenberg, et al., Dis. Colon Rectum, 45, No. 4, 537–543 (2002).PubMedCrossRefGoogle Scholar
  8. 8.
    K. Mimori, K. Yamashita, M. Ohta, et al., Clin. Cancer Res., 10, 8243–8249 (2004).PubMedCrossRefGoogle Scholar
  9. 9.
    M. Nakamura, S. Miyamoto, H. Maeda, et al., Biochem. Biophys. Res. Commun., 333, No. 3, 1011–1016 (2005).PubMedCrossRefGoogle Scholar
  10. 10.
    K. Oba, H. Konno, T. Tanaka, et al., Cancer Lett., 175, No. 1, 45–51 (2002).PubMedCrossRefGoogle Scholar
  11. 11.
    N. Ramnath and P. J. Creaven, Curr. Oncol. Rep., 6, No. 2, 96–102 (2004).PubMedCrossRefGoogle Scholar
  12. 12.
    E. Roeb, M. Arndt, B. Jansen, et al., Int. J. Colorectal Dis., 19, No. 6, 518–524 (2004).PubMedCrossRefGoogle Scholar
  13. 13.
    H. Sato, T. Takino, and H. Miyamori, Cancer Sci., 96, No. 4, 212–217 (2005).PubMedCrossRefGoogle Scholar
  14. 14.
    J. Westermarck and V. M. Kahari, FASEB J., 13, No. 8, 781–792 (1999).PubMedGoogle Scholar
  15. 15.
    S. F. Yang, Y. S. Hsieh, C. L. Lin, et al., Clin. Chim. Acta, 354, Nos. 1–2, 91–99 (2005).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • E. S. Gershtein
    • 1
  • E. A. Korotkova
    • 1
  • A. M. Shcherbakov
    • 1
  • V. V. Prorokov
    • 1
  • D. A. Golovkov
    • 1
  • N. E. Kushlinskii
    • 1
  1. 1.N. N. Blokhin National Cncer Research CenterRussian Academy of Medical SciencesMoscow

Personalised recommendations